Tag: signs

B.C. health-care workers seeing signs of flesh-eating drug

Caring for Downtown Eastside residents struggling with wounds aggravated by the toxic drug supply and poor sanitation is already hard enough, but some Vancouver health-care workers are worried the “flesh-eating drug” is already showing signs in the neighbourhood.

Right now Kilala Lelum, an urban indigenous health co-op, is the only organization operating a low-barrier medical unit in the East Hastings area out of a specially-equipped van, loaded with medical supplies from the overdose antidote Naloxone to a plethora of wound care supplies.

They’re used to patients avoiding the healthcare system and poorly caring for worsening flesh wounds that can turn chronic, but now they’re starting to see signs of people using xylazine, an animal tranquilizer creeping into B.C.’s toxic drug supply and showing signs of its characteristic skin wounds: serious, deep, and worse the longer someone uses drugs tainted with the “tranq dope,” as it’s often called.

“I do have some clients who’ve clearly been into possibly this tranq dope and it scares me, for numerous reasons,” said Kilala Lelum nurse practitioner, Drew Kostyniuk. “A lot of people disconnected, a lot of people have unmet health needs.”

While xylazine has been detected in the toxic drug supply since 2018, the BC Centre for Substance Use issued a bulletin earlier this year warning that they’re increasingly detecting it as a cutting agent in drug samples. The BCCDC warns health-care professionals that Naloxone doesn’t work on the drug, lengthy blackouts and comas have been reported and that they should “consider the presence of xylazine if wounds are slow to heal.”


In the United States, xylazine has been referred to as the “zombie drug” for its effects on users, but the most alarming characteristic has been its impact on the body. 

Aiforia signs a major deal with an Italian Regional Health Authority

Aiforia Technologies PlcInside information, 29 June 2023 at 10:30 a.m. EEST. The Veneto Region Health Authority in Italy has selected Aiforia Technologies Plc as a partner for AI-assisted diagnostics in its clinical pathology laboratories.

The collaboration involves the use of Aiforia software in a total of 12 hospital units for the analysis of tissue samples from breast and prostate cancer patients. The three-year contract covers the analysis of up to 200,000 samples using Aiforia software and the use of an AI model development tool. The total value of the contract is over EUR 1.2 million and the payments will spread over the contract period 2023-2026. The contract also includes an option for a three-year continuation period.


The contract is part of an initiative to digitize the pathology laboratories of the Veneto region hospitals, including, for example, a laboratory information system provided by TESI Group and AI solutions for image analysis by Aiforia. The main provider in this tender is a GPI S.p.A. lead consortium, and Aiforia is one of their subcontractors.


“We are excited to serve the Veneto region with our AI solutions as part of the digitalization process of the anatomical pathology laboratories. This collaboration strengthens our position in the European clinical pathology market and contributes to the recognition that our solutions meet the needs of clinical pathology laboratories,” says Jukka Tapaninen, CEO of Aiforia.


Aiforia does not publish short-term outlooks or financial targets. The company has set short- and medium-term business targets, including acquiring five customers in clinical diagnostics by the end of 2023. This agreement is a significant step towards achieving these goals.



Further inquiries


Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33 61 041 6686 https://investors.aiforia.com/ 


Certified Adviser


UB Securities Ltd, tel. +358 9 25 380

What Are the Signs of Alzheimer’s Disease?

The symptoms of Alzheimer’s can vary from one person to another. Memory problems are typically one of the first signs of the disease. Decline in non-memory aspects of cognition, such as finding the right word, trouble understanding visual images and spatial relationships, and impaired reasoning or judgment, may also signal the early stages of Alzheimer’s. As the disease progresses, symptoms become more severe and include increased confusion and behavior changes.

graphic of a woman sitting at a desk with a laptop looking confused.

For most people with Alzheimer’s — those who have the late-onset variety — symptoms first appear in their mid-60s or later. When the disease develops before age 65, it’s considered early-onset Alzheimer’s, which can begin as early as a person’s 30s, although this is rare.

Alzheimer’s typically progresses clinically in several stages: preclinical, mild (sometimes called early-stage), moderate, and severe (sometimes called late-stage).

Preclinical Alzheimer’s disease

Research suggests that the complex brain changes associated with Alzheimer’s, such as the formation of amyloid plaques or tau tangles, start a decade or more before memory and thinking problems appear. This stage, in which changes in the brain appear before the onset of dementia, is called preclinical Alzheimer’s. However, it’s important to note that not everyone with these brain changes develops dementia.

Signs of Mild Alzheimer’s disease

In mild Alzheimer’s, a person may seem healthy but has more and more trouble making sense of the world around them. The realization that something is wrong often comes gradually to the person and their family. Problems can include:

Alzheimer’s is often diagnosed at this stage.

Signs of moderate Alzheimer’s disease

In this stage, more intensive supervision and care become necessary. These changes and increasing needs can be difficult for many spouses and families. Symptoms may include:

Forgetfulness: Normal or Not? infographic. Click link for full infographic.
Share this infographic and help spread the word about what memory problems are normal and not.
  • Increased confusion and

Eby hints he’s open to bilateral health deals if Ottawa signs on to ‘base’ funding first

British Columbia Premier David Eby hinted he could be open to a bilateral health funding deal with the federal government, provided Ottawa is first willing to sign on to a “base” funding deal with the provinces.

Eby made the comments Wednesday, after Prime Minister Justin Trudeau said he’d invited premiers to a Feb. 7 “working meeting” in Ottawa to hammer out a health-care deal.

Read more:

Feds eye bilateral health deals as Trudeau set to meet with premiers Feb. 7

Read next:

No ‘elevated risk’ of stroke from Pfizer’s bivalent COVID shot, Health Canada says

Canada’s premiers have been seeking an across-the-board, no-strings-attached increase to the Canada Health Transfer, while the Liberal government has signaled it wants bilateral deals with the provinces that could tailor funding increases to regional needs.

Click to play video: 'Premiers call on Trudeau to “set a date” for meeting to increase health transfers'

Premiers call on Trudeau to “set a date” for meeting to increase health transfers

“As I understand it the proposal’s around two badly needed discussions: one is around the base funding for health care that all provinces need universally, but the second is bilateral agreements with the provinces around — each province has its own distinct health issues that we’re facing, and we need to have those unique agreements with Ottawa around those priorities, those areas of strain we’re feeling,” Eby said.

Story continues below advertisement

“My hope is we come out of the meeting on the 7th with an agreement about the base and a commitment and a path towards those bilateral discussions we have to have on our provincial priorities here in B.C.”

Trudeau announced the planned meeting during a news conference Wednesday morning in Hamilton, where the Liberal cabinet was finishing a three-day retreat ahead of the return of Parliament next week.

He said he was eager to negotiate with the premiers, but that no one

Back To Top